Imcyse - The beginning of the end for Type I diabetes: A new view from immunotherapy science

Slide 1

Our mission is to develop a radically new approach for the treatment of severe, chronic autoimmune diseases.

The beginning of the end for Type I diabetes: A new view from immunotherapy science

Jean Van Rampelbergh PhD, VP Clinical & Regulatory at Imcyse SA, introduces ImotopesTM a cutting-edge immunotherapy science with an excellent safety profile that could cure Type 1 diabetes or drastically change treatment options.

Liège, Belgium, January 08, 2021 – More info here

CONTACT

Imcyse S.A.
Denis Bedoret
Chief Executive Officer
Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

FOR MEDIA INQUIRES:
MC Services AG
Anne Hennecke / Brittney Sojeva
Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel.: +49 (0) 211-529-252-14

Address

Headquarters:

Avenue Pré-Aily 14
4031 Liège (Angleur)
BELGIUM

Phone : +32 (0)4 325 1100

Contact


© Imcyse 2022 - All rights reserved